Business · 19/10/2009Updated: 10/17/2026 · 1 min read
FDA Reopens Comment Period for Opioid Drug Risk Evaluation Strategies
Summary
The FDA is extending the public comment period for its opioid drug risk evaluation strategies until October 19, 2010, following continued public interest and a desire to gather more input from stakeholders.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →